Transfusion — CPB 0639 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0639 governing autotransfusion devices and red cell genotyping, effective December 12, 2025. Billing teams need to verify diagnosis and procedure alignment across CPT codes 86890, 86891, and the 0180U–0196U red cell antigen genotyping series before submitting claims.

This update to the Aetna transfusion coverage policy clarifies medical necessity criteria for both autotransfusion/cell saver devices and red blood cell genotyping. The policy now explicitly maps covered indications to specific clinical scenarios — and draws a hard line on what it considers experimental. If your practice bills CPT 86890 or 86891 for autologous blood collection, or any of the U-series red cell antigen codes, this coverage policy change directly affects your claim denial risk.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Transfusion — CPB 0639
Policy Code	CPB 0639
Change Type	Modified
Effective Date	December 12, 2025
Impact Level	High
Specialties Affected	Hematology, Obstetrics/Maternal-Fetal Medicine, Cardiac Surgery, Orthopedic Surgery, Vascular Surgery, Transfusion Medicine, General Surgery
Key Action	Audit diagnosis codes on all red cell genotyping claims and confirm autotransfusion billing meets the 2+ unit blood loss threshold before December 12, 2025

---

Aetna Autotransfusion and Red Cell Genotyping Coverage Criteria and Medical Necessity Requirements 2025

CPB 0639 Aetna covers two distinct service categories: autotransfusion/cell saver devices and red cell genotyping. Each has its own medical necessity rules. Mixing them up in your charge capture will cost you.

Autotransfusion and Cell Saver Devices

Aetna considers autotransfusion medically necessary in three specific scenarios. First, emergency or intra-operative autotransfusion — blood collected from a wound or body cavity, processed, and returned to the patient. Second, hemodilution or cell washing — blood collected and replaced simultaneously with crystalloid or colloid solution. Third, post-operative autotransfusion — typically performed within two hours using a chest tube collection device, following heart surgery or traumatic hemithorax.

CPT 86891 (intra- or postoperative salvage) maps directly to scenarios one and three. CPT 86890 (predeposited autologous blood collection, processing, and storage) applies to pre-surgical collection. Both codes require a procedure context that is expected to deplete significant blood volume.

Here's the threshold that matters most for claim denial prevention: Aetna does not consider autotransfusion or cell saver devices medically necessary for procedures expected to require fewer than two units of blood. That's a bright line. If the expected blood loss doesn't cross that threshold, the device isn't covered — period.

Procedures Aetna recognizes as potential candidates for major blood loss include cardiopulmonary bypass and high-risk cardiac surgery, abdominal aortic surgery, organ transplantation, orthopedic surgery (specifically hip arthroplasty), hysterectomy, vascular femoral grafts, ectopic pregnancy, emergency hemorrhage, and post-operative hemorrhage. These ICD-10 diagnosis codes need to appear on your claim — more on that in the codes section below.

Red Cell Genotyping

This is where the policy gets more expansive — and where billing teams are likely to see the most activity. Aetna considers red cell genotyping medically necessary in seven distinct clinical situations. The antigens covered include C, c, D, E, e, K, k, Jka, Jkb, Fya, Fyb, S, s, and U.

The seven covered scenarios are:

The breadth here is notable. This isn't a narrow carve-out. Aetna's coverage policy for red cell genotyping covers a real range of clinical presentations. The CPT codes that apply are the 0180U through 0196U series — 16 individual red cell antigen genotyping codes, each specific to a different blood group system.

Prior authorization requirements aren't explicitly called out in this bulletin, but complex molecular testing like the U-series codes often triggers payer review. Confirm with Aetna's prior auth lookup tool before billing these codes for the first time in your practice.

---

Aetna Transfusion Exclusions and Non-Covered Indications

Two exclusions appear in CPB 0639. Both carry the experimental, investigational, or unproven designation.

Autotransfusion beyond the three covered scenarios. Any use of autotransfusion or cell saver devices outside the three listed indications is not covered. Aetna is explicit: effectiveness for other indications has not been established.

Hypoxic red blood cells. Aetna considers the use of hypoxic red blood cells experimental for improving energy metabolism and post-transfusion recovery. HCPCS code P9027 — red blood cells, leukocytes reduced, oxygen/carbon dioxide reduced — is specifically listed as not covered for indications in this bulletin. If your facility uses P9027, understand that reimbursement under this policy is off the table. That's not a gray area.

---

Coverage Indications at a Glance

---

Aetna Transfusion Billing Guidelines and Action Items 2025

The effective date is December 12, 2025. Here's what your billing team needs to do before that date.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Transfusion Under CPB 0639

Covered CPT Codes (When Selection Criteria Are Met)

Not Covered / Experimental Codes

Code	Type	Description	Reason Copy
P9027	HCPCS	Red blood cells, leukocytes reduced, oxygen/carbon dioxide reduced, each unit	Not covered for indications listed in CPB 0639 — use of hypoxic red blood cells considered experimental/investigational

Key ICD-10-CM Diagnosis Codes

The full ICD-10 code set under CPB 0639 includes 432 codes. The table above lists the primary groupings most relevant to transfusion and genotyping billing. Confirm complete code mapping against Aetna's published CPB 0639 document, especially for surgical procedures with major blood loss ICD-10 codes.

---